Market Place
Sourcing Support
Sarepta Announces Grants Under Nasdaq Rule 5635(c)(4)
30 Jun 2025 //
BUSINESSWIRE
FDA Investigates Patient Deaths with Sarepta`s Gene Therapy
25 Jun 2025 //
FDA
Sarepta Stock Falls After Second Death Linked to Gene Therapy
16 Jun 2025 //
REUTERS
Sarepta Updates ELEVIDYS Safety for Non-Ambulatory DMD
16 Jun 2025 //
BUSINESSWIRE
FDA Awards Platform Status to Sarepta SRP-9003 Gene Vector
04 Jun 2025 //
BUSINESSWIRE
Sarepta Updates UK Dosing in Elevidys Study for DMD
21 May 2025 //
BUSINESSWIRE
Sarepta Shows Strong EMBARK Data in Gene Therapy Study
16 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics Shares New Endeavor Results in 2-Year-Olds
16 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics` Elevidys Gene Therapy Approved in Japan
13 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Present at BofA Securities Conference
08 May 2025 //
BUSINESSWIRE
Sarepta sees delays in treatment after Elevidys death report
08 May 2025 //
FIERCE PHARMA
Sarepta Therapeutics Reports Q1 2025 Financials and Updates
06 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Announce Q1 2025 Financial Results
22 Apr 2025 //
BUSINESSWIRE
Sarepta Therapeutics Updates Limb-Girdle Muscular Dystrophy Programs
15 Apr 2025 //
BUSINESSWIRE
Sarepta halts gene therapy studies for muscle disorder
05 Apr 2025 //
REUTERS
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
31 Mar 2025 //
BUSINESSWIRE
Patient dies after receiving Sarepta’s DMD gene therapy Elevidys
19 Mar 2025 //
FIERCE PHARMA
Sarepta Opens Applications For 8th Route 79 Duchenne Scholarship
28 Feb 2025 //
BUSINESSWIRE
Sarepta Announces Q4, Full-Year 2024 Results & Developments
26 Feb 2025 //
BUSINESSWIRE
Sarepta Announces Inaugural $600 M Senior Secured Credit Facility
14 Feb 2025 //
BUSINESSWIRE
Sarepta To Announce Q4 & Full-Year 2024 Results
12 Feb 2025 //
BUSINESSWIRE
Arrowhead & Sarepta Close Global License Agreement
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
10 Feb 2025 //
BUSINESSWIRE
Sarepta`s Embark Study Part 2 Shows Elevidys Benefits In DMD
27 Jan 2025 //
BUSINESSWIRE
Sarepta Therapeutics Reports Q4, Full-Year 2024 Net Revenue
13 Jan 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Present at 43rd J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
31 Dec 2024 //
BUSINESSWIRE
Sarepta Wins 115.2 M US Drug Patent Verdict from Nippon Shinyaku
23 Dec 2024 //
REUTERS
Sarepta Completes Enrollment in SRP-9003 Ph 3 Study for LGMD2E/R4
18 Dec 2024 //
BUSINESSWIRE
FDA`s Accelerated Approval Drives Momentum for Fatal Diseases
02 Dec 2024 //
BIOSPACE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
BUSINESSWIRE
Sarepta, Arrowhead ink $1B-plus deal for seven programs
27 Nov 2024 //
FIERCE BIOTECH
Sarepta axes late-phase DMD drug over safety signal
08 Nov 2024 //
FIERCE BIOTECH
Sarepta`s Elevidys blows sales expectations out of the water
07 Nov 2024 //
FIERCE PHARMA
Sarepta Therapeutics Announces Q3 2024 Results & Developments
06 Nov 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule
31 Oct 2024 //
BUSINESSWIRE
Sarepta Therapeutics Q3 2024 Financial Results Announcement
23 Oct 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Rule
30 Sep 2024 //
BUSINESSWIRE
Sarepta To Present At World Muscle Society Congress
26 Sep 2024 //
BUSINESSWIRE
Sarepta Appoints Deirdre Connelly To Board
16 Sep 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces 2024-25 Route 79 Duchenne Scholarship Recipients
05 Sep 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rules
30 Aug 2024 //
BUSINESSWIRE
Sarepta Therapeutics Reports Q2 2024 Results And Corporate Developments
07 Aug 2024 //
BUSINESSWIRE
Sarepta Faces Lower Revenue For Duchenne Gene Therapy
07 Aug 2024 //
ENDPTS
Sarepta Therapeutics Announces Inducement Grants
31 Jul 2024 //
BUSINESSWIRE
Sanofi sues Sarepta, claiming Duchenne gene therapy Elevidys infringes 2 manufacturing patents
31 Jul 2024 //
FIERCE PHARMA
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
29 Jul 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
28 Jun 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
28 Jun 2024 //
BUSINESSWIRE
US FDA approves expanded use of Sarepta`s Duchenne gene therapy; shares jump
21 Jun 2024 //
REUTERS
Great Point Partners acquires German CDMO Lyocontract
13 Jun 2024 //
FIERCE PHARMA
Sarepta Announces Inducement Grants Per Nasdaq Rule
31 May 2024 //
BUSINESSWIRE
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
08 May 2024 //
BIOSPACE
Sarepta Therapeutics executive sells $508,900 in stock
07 May 2024 //
INVESTING
Gene Therapy Pioneer Mendell Named To TIME100 Health List
03 May 2024 //
BUSINESSWIRE
ICER pushes back on FDA`s potential of Sarepta`s gene therapy to full approval
02 May 2024 //
ENDPTS
Sarepta Q1 2024 Results, Recent Corporate Developments
01 May 2024 //
BUSINESSWIRE
FDA decision on Sarepta’s Duchenne gene therapy could come earlier than expected
01 May 2024 //
ENDPTS
Sarepta Therapeutics Inducement Grants Under Nasdaq 5635(c)(4)
30 Apr 2024 //
BUSINESSWIRE
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
24 Apr 2024 //
BUSINESSWIRE
